Page 401 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 20 Melanoma 379

101. Rushton JG, Ertl R, Klein D, et al.: Mutation analysis and gene 122. Brissot HN, Edery EG: Use of indirect lymphography to identify
expression profiling of ocular melanomas in cats, Vet Comp Oncol sentinel lymph node in dogs: a pilot study in 30 tumours, Vet Comp
15:1403–1416, 2017. Oncol 15:740–753, 2017.
VetBooks.ir 102. Fragola JA, Dubielzig RR, Bentley E, et al.: Iridociliary cysts mas- 123. Worley DR: Incorporation of sentinel lymph node mapping in
dogs with mast cell tumours: 20 consecutive procedures, Vet Comp
querading as neoplasia in cats: a morphologic review of 14 cases,
Oncol 12:215–226, 2014.
Vet Ophthalmol 21:125–131, 2017.
103. Chamel G, Abadie J, Albaric O, et al.: Non-ocular melanomas in 124. Liuti T, de VJ, Bosman T, et al.: 67Gallium citrate scintigraphy to
cats: a retrospective study of 30 cases, J Feline Med Surg 19:351– assess metastatic spread in a dog with an oral melanoma, J Small
357, 2017. Anim Pract 50:31–34, 2009.
104. Tuohy JL, Selmic LE, Worley DR, et al.: Outcome following 125. Wallace J, Matthiesen DT, Patnaik AK: Hemimaxillectomy for the
curative-intent surgery for oral melanoma in dogs: 70 cases (1998- treatment of oral tumors in 69 dogs, Vet Surg 21:337–341, 1992.
2011), J Am Vet Med Assoc 245:1266–1273, 2014. 126. Sarowitz BN, Davis GJ, Kim S: Outcome and prognostic factors
105. Owen LN: TNM classification of tumours in domestic animals, ed 3, following curative-intent surgery for oral tumours in dogs: 234
1980. Geneva, Switzerland. cases (2004 to 2014), J Small Anim Pract 58:146–153, 2017.
106. Freeman KP, Hahn KA, Harris FD, et al.: Treatment of dogs 127. Boston SE, Lu X, Culp WT, et al.: Efficacy of systemic adjuvant ther-
with oral melanoma by hypofractionated radiation therapy and apies administered to dogs after excision of oral malignant melano-
platinum-based chemotherapy (1987-1997), J Vet Intern Med mas: 151 cases (2001-2012), J Am Vet Med Assoc 245:401–407, 2014.
17:96–101, 2003. 128. Schwarz PD, Withrow SJ, Curtis CR, et al.: Partial maxillary resec-
107. Proulx DR, Ruslander DM, Dodge RK, et al.: A retrospective anal- tion as a treatment for oral cancer in 61 dogs, J Am Anim Hosp Assoc
ysis of 140 dogs with oral melanoma treated with external beam 27:617–624, 1991.
radiation, Vet Radiol Ultrasound 44:352–359, 2003. 129. Fox LE, Geoghegan SL, Davis LH, et al.: Owner satisfaction with
108. Theon AP, Rodriguez C, Madewell BR: Analysis of prognostic factors partial mandibulectomy or maxillectomy for treatment of oral
and patterns of failure in dogs with malignant oral tumors treated with tumors in 27 dogs, J Am Anim Hosp Assoc 33:25–31, 1997.
megavoltage irradiation, J Am Vet Med Assoc 210:778–784, 1997. 130. Liptak JM, Dernell WS, Rizzo SA, et al.: Partial foot amputation in
109. Williams LE, Packer RA: Association between lymph node size and 11 dogs, J Am Anim Hosp Assoc 41:47–55, 2005.
metastasis in dogs with oral malignant melanoma: 100 cases (1987- 131. Kaufman KL, Mann FA: Short- and long-term outcomes after digit
2001), J Am Vet Med Assoc 222:1234–1236, 2003. amputation in dogs: 33 cases (1999-2011), J Am Vet Med Assoc
110. Skinner OT, Boston SE, Souza CHM: Patterns of lymph node 242:1249–1254, 2013.
metastasis identified following bilateral mandibular and medial ret- 132. Bergman PJ: Immunotherapy in veterinary oncology, Vet Clin
ropharyngeal lymphadenectomy in 31 dogs with malignancies of North Am Small Anim Pract 44:925–939, 2014.
the head, Vet Comp Oncol 15:881–889, 2017. 133. Grosenbaugh DA, Leard AT, Bergman PJ, et al.: Safety and efficacy
111. Herring ES, Smith MM, Robertson JL: Lymph node staging of of a xenogeneic DNA vaccine encoding for human tyrosinase as
oral and maxillofacial neoplasms in 31 dogs and cats, J Vet Dent adjunctive treatment for oral malignant melanoma in dogs follow-
19:122–126, 2002. ing surgical excision of the primary tumor, Am J Vet Res 72:1631–
112. Grimes JA, Matz BM, Christopherson PW, et al.: Agreement 1638, 2011.
between cytology and histopathology for regional lymph node 134. Morton DL: Cytoreductive surgery and adjuvant immunotherapy in
metastasis in dogs with melanocytic neoplasms, Vet Pathol 54:579– the management of metastatic melanoma, Tumori 87:S57–S59, 2001.
587, 2017. 135. Dank G, Rassnick KM, Sokolovsky Y, et al.: Use of adjuvant car-
113. Smith MM: Surgical approach for lymph node staging of oral and boplatin for treatment of dogs with oral malignant melanoma fol-
maxillofacial neoplasms in dogs, J Vet Dent 19:170–174, 2002. lowing surgical excision, Vet Comp Oncol 12:78–84, 2014.
114. Green K, Boston SE: Bilateral removal of the mandibular and 136. Cancedda S, Rohrer BC, Aresu L, et al.: Efficacy and side effects of
medial retropharyngeal lymph nodes through a single ventral mid- radiation therapy in comparison with radiation therapy and temo-
line incision for staging of head and neck cancers in dogs: a descrip- zolomide in the treatment of measurable canine malignant mela-
tion of surgical technique, Vet Comp Oncol 15:208–214, 2017. noma, Vet Comp Oncol 14:e146–e157, 2016.
115. Leong SP, Accortt NA, Essner R, et al.: Impact of sentinel node status 137. Bateman KE, Catton PA, Pennock PW, et al.: 0-7-21 radiation
and other risk factors on the clinical outcome of head and neck mela- therapy for the treatment of canine oral melanoma, J Vet Intern Med
noma patients, Arch Otolaryngol Head Neck Surg 132:370–373, 2006. 8:267–272, 1994.
116. Herring ES, Smith MM, Robertson JL: Lymph node staging of 138. Blackwood L, Dobson JM: Radiotherapy of oral malignant mela-
oral and maxillofacial neoplasms in 31 dogs and cats, J Vet Dent nomas in dogs, J Am Vet Med Assoc 209:98–102, 1996.
19:122–126, 2002. 139. Murphy S, Hayes AM, Blackwood L, et al.: Oral malignant melanoma -
117. Nwogu CE, Kanter PM, Anderson TM: Pulmonary lymphatic the effect of coarse fractionation radiotherapy alone or with adjuvant
mapping in dogs: use of technetium sulfur colloid and isosulfan carboplatin therapy, Vet Comp Oncol 3:222–229, 2005.
blue for pulmonary sentinel lymph node mapping in dogs, Cancer 140. Kawabe M, Mori T, Ito Y, et al.: Outcomes of dogs undergoing
Invest 20:944–947, 2002. radiotherapy for treatment of oral malignant melanoma: 111 cases
118. Yudd AP, Kempf JS, Goydos JS, et al.: Use of sentinel node lym- (2006-2012), J Am Vet Med Assoc 247:1146–1153, 2015.
phoscintigraphy in malignant melanoma, Radiographics 19:343– 141. Tollett MA, Duda L, Brown DC, et al.: Palliative radiation therapy
353, 1999. for solid tumors in dogs: 103 cases (2007-2011), J Am Vet Med
119. Wells S, Bennett A, Walsh P, et al.: Clinical usefulness of intrader- Assoc 248:72–82, 2016.
mal fluorescein and patent blue violet dyes for sentinel lymph node 142. Khan N, Khan MK, Almasan A, et al.: The evolving role of radia-
identification in dogs, Vet Comp Oncol 4:114–122, 2006. tion therapy in the management of malignant melanoma, Int J
120. Suga K, Karino Y, Fujita T, et al.: Cutaneous drainage lymphatic Radiat Oncol Biol Phys 80:645–654, 2011.
map with interstitial multidetector-row computed tomographic 143. Flickinger I, Rutgen BC, Gerner W, et al.: Radiation up-regulates
lymphography using iopamidol: preliminary results, Lymphology the expression of VEGF in a canine oral melanoma cell line, J Vet
40:63–73, 2007. Sci 14:207–214, 2013.
121. Majeski SA, Steffey MA, Fuller M, et al.: Indirect computed tomo- 144. Wergin MC, Ballmer-Hofer K, Roos M, et al.: Preliminary study of
graphic lymphography for iliosacral lymphatic mapping in a cohort plasma vascular endothelial growth factor (VEGF) during low- and
of dogs with anal sac gland adenocarcinoma: technique description, high-dose radiation therapy of dogs with spontaneous tumors, Vet
Vet Radiol Ultrasound 58:295–303, 2017. Radiol Ultrasound 45:247–254, 2004.